AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2022 on Thursday, November 3, 2022, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 3, 2022. Participating in the conference call will be: Steven H. Collis,
→ Google Traductor
If history is any guide, there may be trouble ahead for shares of AmerisourceBergen (NYSE: ABC ). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term … Full story available on Benzinga.com
→ Google Traductor
Biopharma Outlook Therapeutics (OTLK) and U.S. drug distributor AmerisourceBergen (ABC) on Tuesday said they had entered into a commercialization agreement for the anticipated launch of…
→ Google Traductor
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, and AmerisourceBergen (NYSE: ABC), a global healthcare company and leader in specialty pharmaceutical distribution and services, announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).
→ Google Traductor
CHARLESTON, W.Va. (AP) — Walmart and CVS Pharmacy have settled with the state of West Virginia for a combined total of $147 million in a lawsuit over the companies’ roles in contributing to the oversupply of prescription drugs that fueled the opioid epidemic in the country’s most impacted state, Attorney General Patrick Morrisey announced Tuesday. Walmart and CVS were two lawsuits that were part of a larger trial that was pushed back to June of next year along with Kroger and Walgreens. Morrisey recently announced a settlement with Rite Aid for up to $30 million to resolve similar litigation. The lawsuits allege the pharmacies’ contributions to the oversupply of prescription opioids in the state have caused “significant losses through their past and ongoing medical treatment costs, including for minors born addicted to opioids, rehabilitation costs, naloxone costs, medical examiner expenses, self-funded state insurance costs and other forms of losses to address opioid-related afflictions and loss of lives.” It brings the total settlements by the state in opioid lawsuits to $875 million, including $296 million with manufacturers, $400 million with wholesalers and $177.5 million involving pharmacies. “These settlements won’t bring back the lives lost from the opioid epidemic, but these and other settlements will hopefully provide significant help to those affected the most by this crisis in our state,” Morrisey said during a news conference. “This development also avoided a costly and lengthy trial and at the end of the day, West Virginia will have the highest per capita settlement results in the nation fighting for our people.” Walmart agreed to a settlement of just over $65 million and CVS for $82.5 million.
→ Google Traductor
AmerisourceBergen Corporation found using ticker (ABC) now have 12 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 191 and 155 calculating the mean target price we have 173.83. Now with the previous closing price of 139.81 this indicates there is a potential upside of 24.3%. The day 50 moving average is 144.98 and the 200 day MA is 144.08. The market cap for the company is $29,130m. Visit the company website at: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,218m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
→ Google Traductor
AmerisourceBergen (ABC) on Monday said it would acquire PharmaLex Holding GmbH, a provider of specialized services for the life sciences industry, for €1.28B in cash.PharmaLex would…
→ Google Traductor
U.S. drug distributor AmerisourceBergen Corporation said on Monday it would acquire privately held German company PharmaLex Holding GmbH for 1.28 billion euros ($1.30 billion) in cash to expand its global biopharma services platform. AmerisourceBergen will acquire PharmaLex from funds advised by German private-equity firm AUCTUS Capital Partners AG, and the transaction is expected to close […]
→ Google Traductor
AmerisourceBergen Corporation (NYSE:ABC) price on Friday, September 09, fall -0.18% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $147.27. A look at the stock’s price movement, the close in the last trading session was $147.54, moving within a range at $146.63 and $148.02. The beta value (5-Year … AmerisourceBergen Corporation (NYSE: ABC): The Metrics That Matter Right Now Read More »
→ Google Traductor
The national stockpile had been shipping to only about five locations per state and other jurisdictions The post US to expand monkeypox vaccine, drug distribution through AmerisourceBergen contract appeared first on Express Pharma .
→ Google Traductor
The Department of Health and Human Services announced a $20 million contract with AmerisourceBergen to speed up delivery of monkeypox vaccines nationwide.
→ Google Traductor
The Department of Health and Human Services (HHS) on Tuesday announced it was awarding a nearly $20 million contract to AmerisourceBergen to expand the distributions of treatments and vaccines to treat the ongoing monkeypox outbreak. The $19.8 million contract to AmerisourceBergen, one of the largest drug distribution companies in the U.S., will allow for the…
→ Google Traductor
The U.S. Department of Health and Human Services ((HHS)) on Tuesday said it had awarded a $19.8M contract to drug distributor AmerisourceBergen (ABC) to expand and speed up the…
→ Google Traductor
NEW YORK — The U.S. Department of Health and Human Services (HHS) on Tuesday said it will significantly expand the number of distribution locations for monkeypox vaccines and treatments through a new $20 million contract with AmerisourceBergen Corp. Under the new contract, HHS said it will be able to make up to 2,500 shipments per […]
→ Google Traductor
CONCORD, N.H. (AP) — Drugmaker Johnson & Johnson has agreed to pay $40.5 million in a settlement with New Hampshire over its role in the opioid addiction crisis, days before the case was scheduled for trial, the state attorney general’s office said Thursday. The state filed a lawsuit against Johnson & Johnson and a subsidiary in 2018, alleging that they aggressively marketed their opioids to prescribers and patients in New Hampshire and misrepresented that their opioids were safer than other alternatives. The lawsuit also alleged that Johnson & Johnson made misleading statements about opioids; misrepresented that its opioids were rarely addictive when used for chronic pain; and targeted vulnerable populations, such as the elderly. “This resolution provides a positive step forward in ensuring these devastating business practices are not repeated, and that resources are allocated to help stem the tide of the opioid crisis,” Gov. Chris Sununu said in a statement. Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., denied the state’s claims, saying it truthfully marketed its prescription opioids, which accounted for a small share of the opioid medications prescribed in New Hampshire, complied with all applicable laws and regulations, did not cause the harm alleged by the state. “This settlement is not an admission of liability or wrongdoing and marks continued progress in resolving opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States,” Johnson & Johnson said in a statement. “The Company will continue to defend against any litigation that the final agreement does not resolve.” New Hampshire was one of a few states that did not join a national settlement with the company in February because its opioid crisis was “particularly severe” and because the state had already devoted “significant litigation resources” in preparation for trial, the attorney general office’s news release said.
→ Google Traductor
AmerisourceBergen Corporation found using ticker (ABC) have now 13 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 191 and 150 and has a mean target at 172. With the stocks previous close at 146.19 this now indicates there is a potential upside of 17.7%. The 50 day moving average now sits at 144.43 and the 200 day moving average is 142.52. The company has a market cap of $30,533m. Find out more information at: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $35,924m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
→ Google Traductor
AmerisourceBergen Corporation found using ticker (ABC) now have 13 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 191 and 150 with the average target price sitting at 171.92. Given that the stocks previous close was at 149.91 this would indicate that there is a potential upside of 14.7%. The 50 day moving average now sits at 143.86 and the 200 moving average now moves to 141.97. The company has a market capitalisation of $31,509m. You can visit the company''s website by visiting: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,136m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
→ Google Traductor
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- FMW Media''s New To The Street / Newsmax TV announces its 377th show line-up, which features the following seven (7) Corporate interviews, airing Sunday, August 21, 2022, 10-11 AM ET: 1). Tonix Pharmaceuticals, Inc.''s (NASDAQ: TNXP ) ($TNXP) interview with Dr. Seth Lederman, MD, and CEO. 2). PetVivo Holdings, Inc.''s (NASDAQ: PETV ) (NASDAQ: PETVW ) ($PETV) interview with John Lai, CEO & President. 3). Verde Bio Holdings, Inc.''s (OTCQB: VBHI ) ($VBHI) interview with Scott Cox, CEO. 4). HCM Staffing & Consulting (HCM) interviews with Eddie Bright, Jr. CEO, Valarie Mackey, CEO- WrightNow Solutions , and Yvette Pegues, Chief Diversity Officer (CDO) - Your Invisible Disability GroupDisability Group . 5). Sekur Private Data, Ltd.''s (OTCQX: SWISF ) (CSE: SKUR ) (FRA: GDT0) interview with Mr. Alain Ghiai, CEO. 6). "Unstoppable Women Entrepreneurs Segment" – Coastal Kapital, LLC''s interview with Kortney Murray, CEO/Founder. 7). "Sekur Privacy & Sekur Security Segment" interview with internet privacy expert Mr.
→ Google Traductor
AmerisourceBergen Corporation has recently pulled back and provides a potential entry point for investors. Long term, the industry should maintain its 1% share of the U.S. market.
→ Google Traductor
Nasdaq''s Randall Hopkins spoke with AmerisourceBergen’s Jim Cleary, Executive Vice President and Chief Financial Officer, and Susan Lorenz-Fisher, Senior Vice President of Corporate Responsibility and Sustainability, about AmerisourceBergen’s ESG initiatives.
→ Google Traductor
AmerisourceBergen Corporation found using ticker (ABC) now have 13 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 191 and 150 and has a mean target at 171.92. Now with the previous closing price of 147.76 this would imply there is a potential upside of 16.4%. There is a 50 day moving average of 143.52 while the 200 day moving average is 141.25. The company has a market capitalisation of $31,192m. Company Website: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,293m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
→ Google Traductor
AmerisourceBergen Corporation (NYSE:ABC) concluded the trading at $150.50 on Friday, August 12 with a rise of 1.54% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $148.22 and 5Y monthly beta was reading 0.49 with its price kept floating in the range … AmerisourceBergen Corporation (ABC) Could Be Worth Considering For The Next Few Weeks Read More »
→ Google Traductor
Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors
→ Google Traductor
Eli Lilly (LLY) announced that the FDA had updated the authorization granted for its COVID-19 antibody therapy bebtelovimab allowing its commercial availability from next week through…
→ Google Traductor
AmerisourceBergen Corporation found using ticker (ABC) now have 12 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 188 and 150 calculating the average target price we see 170.75. With the stocks previous close at 139.27 this would indicate that there is a potential upside of 22.6%. The 50 day MA is 144.36 and the 200 day moving average is 140.67. The market cap for the company is $29,288m. You can visit the company''s website by visiting: https://www.amerisourcebergen.com [stock_market_widget type="chart" template="basic" color="green" assets="ABC" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $35,908m based on the market concensus. AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
→ Google Traductor
Tennessee’s attorney general said Wednesday he has sued Walgreens, accusing the drugstore chain of contributing to the state’s opioid crisis by failing to maintain effective controls against the abuse of prescription pain pills. The lawsuit seeking unspecified civil penalties was filed in Knox County Circuit Court by Attorney General Herbert H. Slatery III and alleges violations of Tennessee’s Consumer Protection Act. The lawsuit said that between 2006 and 2020, Walgreens retail stores in Tennessee dispensed more than 1.1 billion oxycodone and hydrocodone pills. One pharmacy alone in Jamestown dispensed enough opioids over that period to supply each resident with 2,104 pills. “Walgreens did not flood the State of Tennessee with opioids by accident,” Slatery said in a statement. “Rather, the fuel that Walgreens added to the fire of the opioid epidemic was the result of knowing — or willfully ignorant — corporate decisions. Walgreens ignored numerous red flags and failed to detect and prevent the abuse and diversion of dangerous narcotics.” Walgreens did not offer immediate comment Wednesday.
→ Google Traductor
AmerisourceBergen Corp''s (NYSE: ABC ) Q3 FY22 adjusted EPS reached $2.62 , up 21.3% Y/Y, beating the consensus of $2.57. Revenue of $60.1 billion increased by 12.5% Y/Y, beating the analyst consensus of $59.03 billion, reflecting a 120.3% increase in revenue within International Healthcare Solutions, primarily driven by the June 2021 acquisition of Alliance … Full story available on Benzinga.com
→ Google Traductor
Amerisourcebergen Corp (NYSE:NYSE:ABC) Q3 2022 Earnings Conference Call August 03, 2022, 08:30 ET Company Participants Bennett Murphy - SVP, IR Steven Collis - Chairman, President & CEO…
→ Google Traductor
AmerisourceBergen Corp. (ABC) on Wednesday reported that net income attributable to the company for the third quarter surged to $406.96 million or $1.92 per share from $292.12 million or $1.40 per share in the prior-year quarter.
→ Google Traductor
Ulta is just the latest corporate venture fund. The Home Depot, Chipotle, AmerisourceBergen and Booz Allen Hamilton also announced funds this year, bringing a total of $450 million to the table.
→ Google Traductor
Ulta is just the latest corporate venture fund. The Home Depot, Chipotle, AmerisourceBergen and Booz Allen Hamilton also announced funds this year, bringing a total of $450 million to the table.
→ Google Traductor
AmerisourceBergen (ABC) is scheduled to announce Q3 earnings results on Wednesday, August 3rd, before market open.The consensus EPS Estimate is $2.56 (+18.5% Y/Y) and the consensus…
→ Google Traductor
CHARLESTON, W.Va. (AP) — West Virginia cities and counties reached a $400 million tentative settlement with three major U.S. drug distributors, lawyers announced Monday. In a lawsuit in state court, the cities and counties accused the distributors of fueling the opioid epidemic. The companies are AmerisourceBergen, Cardinal Health and McKesson. The funds will be distributed over 12 years. “This is a monumental settlement for the state of West Virginia, and it’s been a battle that’s been waged by a lot of families, a lot of communities,” Wheeling attorney Bob Fitzsimmons told news outlets. “A lot of bad things have happened as a result of the opioid epidemic.” Fitzsimmons and Huntington attorney Paul Farrell Jr. said the individual counties and municipalities still must approve the settlement. Lauren Esposito, vice president of external and executive communications for AmerisourceBergen, said the settlement will avoid years of litigation and help get resources to areas affected by opioid misuse, as well as make sure health care facilities are able to access medications that patients and providers need, news outlets reported.
→ Google Traductor
Three leading drug distributors in the U.S., McKesson (MCK), AmerisourceBergen (ABC), and Cardinal Health (CAH), have struck a $400M settlement with West Virginia''s cities and counties…
→ Google Traductor
West Virginia’s cities and counties reached a $400 million settlement on Monday with drug distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, resolving the local governments’ allegations that the three companies fueled an opioid crisis in the state. More than 100 local governments had sued the drug distributors, alleging they recklessly oversupplied West Virginia […]
→ Google Traductor
HARRISBURG, Pa. (AP) — A former opioid manufacturer has agreed in principle to pay up to $2.4 billion in a deal with a dozen states over its marketing and product safety practices, state attorneys general announced Friday. The company, Allergan, is now part of AbbVie but sold its generics division Actavis, including its opioid products, to Teva Pharmaceuticals six years ago. Under the settlement, payments will be made to state and local governments, Pennsylvania Attorney General Josh Shapiro said. The agreement means pharma companies have consented to pay more than $40 billion to settle opioid crisis claims regarding manufacturers and distributors, The Associated Press has found. The agreement came days after a similar, $4.3 billion agreement was reached with Teva Pharmaceuticals. A message seeking comment were left Friday with a corporate spokesperson for Teva. Shapiro said the settlement involved claims that Allergan, which produced Norco and Kadian brand generic opioids, downplayed the risk of addiction in marketing and did not act sufficiently to prevent the drugs from being improperly diverted. “No amount of money will bring back the lives we lost, but today’s agreement will help ensure we can fund the programs Pennsylvania counties need for our communities to recover from this crisis,” Shapiro said in a statement.
→ Google Traductor
Cardinal Health sees its Relative Strength Rating enter the 80-plus level.
→ Google Traductor
Quipt Home Medical (QIPT) on Monday said it had entered into a supply and distribution agreement for medical supplies with a business of U.S.-drug distributor Cardinal Health…
→ Google Traductor
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2022 on Wednesday, August 3, 2022, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 3, 2022. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executiv
→ Google Traductor
Oklahoma reached a $250M settlement with AmerisourceBergen (ABC), McKesson (MCK) and Cardinal (CAH) to resolve claims that the drug distributors fueled the opioid crisis."Money…
→ Google Traductor
Oklahoma Attorney General John O’Connor said on Monday his state reached a $250 million settlement with Amerisource Bergen Corp, Cardinal Health Inc and McKesson Corp to resolve allegations the drug distributors contributed to the opioid epidemic in the state. (Reporting by Tom Hals in Wilmington, Delaware)
→ Google Traductor